Effects of Aliskiren Monotherapy on Chronic Kidney Disease: A Systematic Review and Meta‐Analysis of Blood Pressure and Urinary Protein Excretion Outcomes

Read full text Summarise with VIRAT
Authors: N. M. Mahmudul Alam Bhuiya, Joshua Caballero, Henry Nolan Young, Lorenzo Villa Zapata
Cited by: 0
References: 39

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Aliskiren has been proposed as an alternative for renin-angiotensin system blockage in chronic kidney disease (CKD); however, its efficacy and safety remain uncertain. The objective of this study was to evaluate the antihypertensive and antiproteinuric effects of aliskiren monotherapy in patients with CKD and hypertension. PRISMA 2020 guidelines were adopted for this systematic review and meta-analysis (PROSPERO: CRD420251024983). Relevant studies published (January 2001-February 2026) were identified in PubMed and Web of Science that compared aliskiren monotherapy with placebo or other antihypertensives in adults with CKD. Random-effects models were used to assess changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), and urinary protein excretion. Risk of bias was evaluated using the RoB 2 and ROBINS-I tools. Nine trials (eight for quantitative analysis) were included. Overall, aliskiren did not significantly reduce SBP (MD -2.91 mmHg; 95% CI -8.74 to 2.91; p = 0.33) or DBP (n = 300; MD -1.35 mmHg; 95% CI -4.72 to 2.02; p = 0.43). In subgroup analysis, short-term trials (

Fields of Study & Subjects

Renin-Angiotensin System Studies Chronic Kidney Disease and Diabetes Blood Pressure and Hypertension Studies

Publication details

Journal / source
Journal of Clinical Hypertension
Volume
28
Issue
3
Pages
e70237–e70237
Publication date
1 March 2026
Language
EN